Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › IA › CEDAR RAPIDS › MEDICAL LABORATORIES OF EASTERN IOWA LC

MEDICAL LABORATORIES OF EASTERN IOWA LC

NPI: 1477876514 · CEDAR RAPIDS, IA 52402 · Clinical Medical Laboratory · NPI assigned 03/03/2010

$14.45M
Total Medicaid Paid
638,696
Total Claims
601,578
Beneficiaries
177
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialTOWNSEND, THEODORE (PRESIDENT/CEO)
NPI Enumeration Date03/03/2010

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 92,017 $1.62M
2019 89,494 $1.79M
2020 74,091 $1.73M
2021 106,020 $3.91M
2022 114,423 $2.66M
2023 102,236 $1.71M
2024 60,415 $1.02M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 26,578 25,515 $2.01M
0202U Oncology (prostate), multianalyte, gene expression profiling 4,625 4,511 $1.79M
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 34,672 33,149 $1.14M
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 5,732 5,552 $754K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 4,823 4,580 $651K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 4,053 3,910 $523K
0240U 4,120 3,994 $497K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 18,600 17,886 $430K
80050 General health panel 8,074 7,809 $370K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 9,221 8,459 $359K
87507 993 960 $326K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 9,099 8,655 $302K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 9,094 8,650 $302K
36415 Collection of venous blood by venipuncture 74,984 68,217 $281K
80061 Lipid panel 24,573 23,794 $275K
84443 Thyroid stimulating hormone (TSH) 20,442 19,518 $274K
80053 Comprehensive metabolic panel 23,119 21,969 $205K
87581 4,825 4,576 $177K
87486 4,827 4,577 $177K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 6,441 5,929 $172K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 26,219 23,913 $170K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 6,563 6,360 $159K
83036 Hemoglobin; glycosylated (A1C) 17,986 17,390 $139K
87660 7,298 6,929 $135K
87480 7,300 6,929 $135K
87510 7,302 6,931 $135K
80048 Basic metabolic panel (calcium, ionized) 17,866 16,674 $127K
83655 9,526 9,262 $113K
86003 2,278 1,764 $110K
87086 Culture, bacterial; quantitative colony count, urine 14,952 13,878 $106K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 5,056 4,870 $105K
84439 13,606 12,960 $103K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 2,062 2,004 $92K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,622 1,525 $75K
86738 5,790 5,596 $75K
82728 5,558 5,344 $63K
85027 9,816 9,448 $57K
86480 1,025 985 $53K
86235 647 610 $51K
87430 3,428 3,308 $51K
86141 4,027 3,680 $48K
87077 6,157 5,860 $48K
86803 3,924 3,777 $48K
87631 978 949 $47K
87186 5,217 4,966 $41K
83970 1,289 1,248 $40K
82607 3,083 2,969 $38K
84153 2,221 2,167 $37K
81001 12,677 11,729 $37K
81025 4,772 4,592 $36K
87506 168 149 $34K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 894 875 $33K
86481 419 398 $32K
84403 1,351 1,275 $31K
80074 749 721 $29K
86780 2,338 2,260 $27K
82043 5,367 5,203 $26K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 840 824 $24K
36416 17,240 15,995 $23K
84481 1,457 1,382 $22K
86225 1,759 1,699 $21K
83516 1,687 1,608 $21K
83550 2,788 2,703 $20K
83001 1,237 1,199 $20K
87529 457 343 $20K
84702 1,590 1,371 $20K
83540 3,606 3,492 $20K
86038 1,738 1,685 $19K
82746 1,405 1,371 $17K
82784 1,744 1,686 $17K
85610 5,502 3,899 $17K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 188 181 $16K
81003 7,717 7,370 $16K
82570 3,647 3,487 $15K
83735 2,849 2,557 $15K
85018 6,483 6,334 $15K
86618 849 826 $13K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 178 171 $13K
83690 2,008 1,933 $12K
0353U 2,361 2,252 $12K
80076 1,774 1,652 $12K
87807 918 881 $12K
87070 1,489 1,430 $12K
82670 485 462 $11K
84703 1,548 1,486 $11K
85652 4,408 4,206 $11K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 173 165 $10K
82247 2,189 1,338 $10K
84402 435 412 $10K
83880 311 303 $10K
86364 938 905 $9K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 139 127 $9K
86376 712 683 $9K
83002 555 528 $9K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 270 260 $8K
86308 1,733 1,604 $8K
82533 492 427 $7K
86592 1,731 1,656 $7K
82947 2,106 2,001 $7K
84146 401 386 $7K
84460 1,616 1,548 $7K
87505 61 61 $7K
84550 1,748 1,689 $7K
85730 1,440 1,340 $7K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 56 45 $6K
84450 1,562 1,494 $6K
82150 1,052 1,020 $6K
87205 1,557 1,495 $6K
86431 1,102 1,081 $6K
86140 1,207 1,145 $5K
87340 571 530 $5K
82274 282 275 $4K
83520 232 223 $4K
85379 476 456 $4K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) 109 106 $4K
86695 243 240 $4K
80069 544 441 $4K
82248 772 634 $4K
83721 527 463 $4K
84156 1,209 1,136 $3K
82465 1,044 873 $3K
87641 114 103 $3K
88305 Level IV - Surgical pathology, gross and microscopic examination 39 38 $3K
82785 195 190 $3K
86696 153 152 $3K
86147 56 51 $2K
87522 Neg quan hep c or qual rna 60 55 $2K
87338 167 160 $2K
83921 94 93 $2K
86146 38 38 $1K
84100 354 328 $1K
87046 56 54 $1K
85390 103 88 $1K
85014 601 579 $1K
87210 215 209 $1K
86706 127 123 $1K
82550 188 171 $1K
84480 73 71 $971.51
82962 490 461 $966.41
85613 138 117 $956.85
80164 90 84 $943.38
87536 15 14 $939.09
88141 41 41 $903.96
80177 83 73 $893.56
82977 158 152 $874.64
82565 185 169 $699.38
84165 71 70 $592.21
86694 31 26 $538.78
87081 93 89 $518.70
86334 31 31 $482.94
83525 40 39 $457.22
86812 30 28 $449.28
87045 56 54 $433.72
85060 113 107 $432.64
84484 37 36 $405.52
86359 14 13 $398.25
86200 29 27 $332.10
87493 12 12 $275.44
86360 14 13 $270.00
G0103 Prostate cancer screening; prostate specific antigen test (psa) 30 29 $236.56
87899 12 12 $233.89
82627 15 14 $232.32
86800 12 12 $190.55
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) 53 53 $157.32
87324 13 12 $140.60
81015 60 55 $137.68
86255 14 12 $127.26
84132 33 29 $126.34
85046 27 26 $124.43
86705 12 12 $113.88
87177 12 12 $106.52
99001 39 30 $10.44
3046F 168 160 $0.00
3051F 228 222 $0.00
0352U 2,257 2,147 $0.00
3044F 1,211 1,178 $0.00
3052F 123 121 $0.00